Recent 8-K filings for KAPA
Highest-materiality recent filing
Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics
- Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).
- Consideration includes 16.5% of Kairos shares on fully diluted basis, $15M milestone upon FDA submission, and 2% royalty on U.S. net revenues.
-
Kairos Pharma issues investor presentation for LD Micro Invitational; no material new data disclosed
Company issued investor presentation for presentation at LD Micro Invitational on May 18-19, 2026.
-
Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics
Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).
-
Kairos Pharma signs term sheet to acquire two lung cancer assets from Celyn Therapeutics
Worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) for NSCLC.
-
Kairos Pharma grants $950K RSUs to executives; $227.5K cash bonuses for FY2024
Total RSU grant value $950K at $1.31/share, vesting Oct 8, 2026 with change-of-control acceleration.
-
Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025
On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.
-
Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months
Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.
-
Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data
Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.
-
Kairos Pharma to present initial Phase 1 data for ENV105 in NSCLC at World Lung Cancer Conference
Dr. Karen Reckamp to present combination of ENV105 (carotuximab) with osimertinib for advanced EGFR-mutated NSCLC.
-
Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC
No dose-limiting toxicities or unexpected adverse events in first 10 patients.
-
Kairos Pharma shareholders approve dilutive stock issuance, elect directors, enter IR pact
Entered one-year IR services agreement with Barretto Pacific Corp for $170,000 fee.
-
Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518
KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.
-
Kairos Pharma replaces auditor Marcum with Weinberg; 2023 report had going concern
Audit committee dismissed Marcum LLP and appointed Weinberg & Company effective April 23, 2025.
-
Kairos Pharma CEO letter updates ENV105 trials, DoD grant, and analyst coverage
ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer trials; interim efficacy data expected end of Q2 2025.
-
Kairos Pharma publishes study showing CD105 blockade restores osimertinib sensitivity in NSCLC
Study in Drug Resistance Updates shows CD105 upregulation drives resistance to EGFR-targeted therapy osimertinib.
-
Kairos Pharma presents preclinical data for KROS 101 and KROS 401 at AACR IO
KROS 101 (GITR agonist) inhibited tumor growth in melanoma model and increased CD4+/CD8+ T cell proliferation.
-
KROS 101, a GITR agonist, enhanced T cell infiltration and proliferation in mouse melanoma models and human glioblastoma in vitro.
-
Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants
Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.
-
Kairos Pharma raises $3.5M in PIPE offering at $1.40/unit with warrants
Raises $3.5M gross from sale of units at $1.40/Common Unit and $1.399/Pre-Funded Unit.
-
Kairos Pharma appoints Rahul Singhvi as director, replacing Rosemary Mazanet
Dr. Rosemary Mazanet resigned from board effective upon appointment of new independent director; not due to disagreement.
-
Kairos Pharma approved for dual listing on Upstream; trading starts Nov 26
Approved to dual list shares on Upstream, a MERJ Exchange market and global trading app.
-
Kairos Pharma CEO to speak at Maxim Healthcare Virtual Summit; investor deck updated
CEO Dr. John S. Yu will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit (Oct 15-17).
-
Kairos Pharma enters consulting pact with Cross Current for $700K total compensation
Consulting agreement for $200,000 cash and restricted shares valued at $500,000, subject to a six-month true-up to maintain $500K value.
-
Kairos Pharma enters two service agreements: $615K cash + 50K RSUs
CEO.CA Technologies to provide advertising and consulting for $250,000 over 12 months.
-
Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials
Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.
-
Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA
Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.55 · Most common event other_material